Supporting information for

Bis(2-methoxyethyl)ether promoted intramolecular acceptorless dehydrogenative coupling to construct structurally diverse quinazolinones by molecular oxygen

Rongrong Zhao[§], Simiaomiao Wen[§], Hao Fu, Mengna Liu, Qixing Liu* and Haifeng Zhou*

Research Center of Green Pharmaceutical Technology and Process, Hubei Key Laboratory of Natural Products Research and Development, College of Biological and Pharmaceutical Sciences, China Three Gorges University, 443002, Yichang, China.

E-mail: qixingliu86@163.com; zhouhf@ctgu.edu.cn

§ These authors contributed equally to this work.

1. General information	2
 2. General procedure for synthesis of substrates	2
5. Control experiments	3
6. Analytical data of the products	4
7. NMR spectra	
8. HRMS spectra	40

1. General information

Unless otherwise noted, all reagents, catalysts and solvents were purchased from commercial suppliers and used without further purification. Column chromatography was performed with silica gel (200-300 mesh). NMR spectra were recorded on Bruker AVANCE III (400 MHz) spectrometers. CDCl₃ or DMSO-*d*6 was the solvent used for the NMR analysis, with tetramethyl silane as an internal standard. Chemical shifts were reported up field to TMS (0.00 ppm) for ¹H NMR and relative to CDCl₃ (77.0 ppm) for ¹³C NMR. HRMS spectra were acquired using a waters G2-XS QTof mass spectrometer.

2. General procedure for synthesis of substrates

2.1 A typical procedure for the synthesis of 1^[1]



To a solution of K_2CO_3 (6.6 mmol) in DMF (5 mL), 1,2,3,4-tetrahydroisoquinoline (6.6 mmol) and 2-fluorobenzonitrile (6 mmol) were added. The reaction mixture was stirred at 140 °C for 12 h. The mixture was poured into water (100 mL), and followed by the extraction with ethyl acetate (25 mL × 3). The combined organic layer was dried over anhydrous MgSO₄ and concentrated under vacuum. The residue was added to a mixture of AcOH-H₂SO₄ (3 mL, V/V = 2: 1). The resulting mixture was stirred at 120 °C for 2 h and then slowly poured into ice-cold water (100 mL). The pH of the solution was adjusted to 7 by adding aqueous NaOH solution (1 M). The solution was extracted with ethyl acetate (20 mL × 3). The combined organic layer was dried over anhydrous MgSO₄ and concentrated under vacuum. The residue was purified by silica gel flash column chromatography to give compound **1**.

2.2 A typical procedure for the synthesis of 3^[2]



A mixture of 2-aminobenzamide (1.5 mmol), K_2CO_3 (1.5 mmol), NaI (1.5 mmol), and benzyl bromide (2.0 mmol) in DMF (10 mL) was stirred at room temperature for 24 hours. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO₄, and concentrated in vacuo. The residue was purified by silica gel flash column chromatography to give compound **3**.

3. General procedure for the synthesis of compound 2 or 4 or 6

The substrate 2-(3,4-dihydroisoquinolin-2(1H)-yl)benzamide **1** or 2-(benzylamino)benzamide **3** (0.5 mmol), or analogue **5**, BME (1 mL) were added to a 10 mL Schlenk tube. The tube was evacuated and filled with oxygen three times. The mixture was stirred at 120 °C for 2 hours under oxygen atmosphere with an O_2 balloon. After cooling, the mixture was subjected to a silica gel column chromatography to isolate product **2** or **4** or **6**.

4. Gram-scale synthesis of compound 2a



2-(3,4-Dihydroisoquinolin-2-yl)benzamide (**1a**, 1.26 g, 5 mmol) and BME (10 mL) were added to a 25 mL round-bottom flask. The flask was evacuated and filled with oxygen three times. The mixture was stirred at 120 °C for 9 hours under oxygen atmosphere with an O₂ balloon. After cooling, the mixture was subjected to a silica gel column chromatography to isolate product **2a** (1.12 g, 90% yield).

5. Control experiments



2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzamide **1a** (0.3 mmol) and BME (1 mL) were added to a 10 mL Schlenk tube. The tube was evacuated and filled with nitrogen three times. The mixture was stirred at 120 °C for 10 hours under nitrogen atmosphere with a N₂ balloon. After cooling, the product **2a** was not detected.



2-(3,4-Dihydroisoquinolin-2(1H)-yl)benzamide **1a** (0.3 mmol), BME (1 mL), and 2,2,6,6tetramethylpiperidine-*N*-oxyl (TEMPO, 0.6 mmol) were added to a 10 mL Schlenk tube. The tube was evacuated and filled with oxygen three times. The mixture was stirred at 120 °C for 2 hours under oxygen atmosphere with an O_2 balloon. After cooling, the mixture was subjected to silica gel column chromatography to isolate product **2a** (30 mg, 40%).

6. Analytical data of the products

12,13-dihydro-6H-isoquinolino[2,1-*a*]quinazolin-6-one (2a)^[1]



94% yield (117 mg). ¹**H NMR** (400 MHz, CDCl₃): δ = 8.53 (dd, J₁ = 7.6 Hz, J₂ = 1.2 Hz, 1H), 8.38 (dd, J₁ = 7.6 Hz, J₂ = 1.6 Hz, 1H), 7.77-7.70 (m, 1H), 7.57-7.37 (m, 4H), 7.28 (dd, J₁ = 7.2 Hz, J₂ = 1.2 Hz, 1H), 4.35 (t, J = 6.8 Hz,

2H), 3.25 (t, *J* = 6.4 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 169.94, 155.57, 141.20, 136.27, 134.29, 133.22, 130.04, 129.56, 129.31, 128.29, 127.48, 126.33, 120.85, 114.40, 43.77, 27.59.

7-methoxy-12,13-dihydro-6H-isoquinolino[2,1-a]quinazolin-6-one (2b)



82% yield (114 mg). ¹**H NMR** (400 MHz, CDCl₃): δ = 8.37 (dd, J_1 = 8.0 Hz, J_2 = 1.5 Hz, 1H), 7.51 (t, J = 8.4 Hz, 1H), 7.42-7.36 (m, 1H), 7.28 (t, J = 8.0 Hz, 1H), 7.21 (d, J = 7.2 Hz, 1H), 7.01 (d, J = 8.4 Hz, 1H), 6.80 (d, J = 8.4 Hz, 1H), 4.19 (t, J = 6.8 Hz, 2H), 3.93 (s, 3H), 3.19 (t, J = 6.8 Hz,

2H). ¹³C NMR (100 MHz, CDCl₃): δ = 167.84, 160.68, 153.60, 143.27, 135.79, 133.91, 132.34, 129.11, 128.94, 127.48, 126.83, 110.34, 107.14, 105.61, 56.40, 43.95, 27.04. **HRMS** (ESI) calcd. for C₁₇H₁₅N₂O₂ ([M+H]⁺): 279.1134, Found: 279.1140.

9-methyl-12,13-dihydro-6H-isoquinolino[2,1-a]quinazolin-6-one (2c)^[1]



82% yield (108 mg). ¹**H NMR** (400 MHz, CDCl₃): δ = 8.49 (dd, J_I = 8.0 Hz, J_2 = 1.6 Hz, 1H), 8.22 (d, J = 8.0 Hz, 1H), 7.48 (dt, J = 7.6, 1.2 Hz, 1H), 7.38-7.20 (m, 4H), 4.32 (t, J = 6.8 Hz, 2H), 3.25 (t, J = 6.4 Hz, 2H),

2.51 (s, 3H). ¹³**C NMR** (100 MHz, CDCl₃): *δ* = 169.43, 154.85, 144.82, 140.77, 135.83, 132.60, 129.48, 129.11, 128.58, 127.67, 127.19, 126.99, 118.08, 113.99, 43.19, 27.08, 22.42.

8-(trifluoromethyl)-12,13-dihydro-6H-isoquinolino[2,1-a]quinazolin-6-one (2d) [1]



 $(100 \text{ MHz}, \text{CDCl}_3): \delta = 168.34, 155.98, 142.89, 135.82, 133.26, 130.11 (q, J = 3.3 \text{ Hz}), 129.91,$ 128.71, 128.05, 127.79, 127.10, 126.90 (q, J = 3.8 Hz), 126.87 (q, J = 270.3 Hz), 120.27, 114.75, 43.70, 27.11.

7-fluoro-12,13-dihydro-6H-isoquinolino[2,1-*a*]quinazolin-6-one (2e)



80% yield (107 mg). ¹H NMR (400 MHz, CDCl₃): δ = 8.48 (d, J = 8.0 Hz, 1H), 7.70-7.65 (m, 1H), 7.52 (t, J=7.2 Hz, 1H), 7.39-7.29 (m, 3H), 7.15-7.06 (m, 1H), 4.34 (t, J = 6.8 Hz, 2H), 3.31 (t, J = 6.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): $\delta = 160.75$, 154.73, 142.89, 135.80, 134.12 (d, J = 11.0 Hz), 132.88, 129.54, 128.87(d, *J* =35.9 Hz), 127.8, 126.98, 126.14, 122.46, 112.76 (d, *J* =21.0 Hz), 109.69, 44.10, 27.07.

HRMS (ESI) calcd. for C₁₆H₁₂FN₂O ([M+H]⁺): 267.0934, Found: 267.0938.

9-fluoro-12,13-dihydro-6H-isoquinolino[2,1-*a*]quinazolin-6-one (2f)



79% yield (105 mg). ¹H NMR (400 MHz, CDCl₃): $\delta = 8.27-8.12$ (m, 2H), 7.54 (t, J = 7.2 Hz, 1H), 7.46-.40 (m, 2H), 7.34-7.29 (m, 2H), 4.08 (t, J = 6.8 Hz, 2H), 3.21 (t, J = 6.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): $\delta =$ 164.36, 164.13, 161.85 (d, *J* = 246.4 Hz), 147.72 (d, *J* = 11.7 Hz), 138.21,

132.67, 132.48 (d, J = 3.2 Hz), 129.09, 128.99, 127.46, 127.11, 119.88 (d, J = 2.9 Hz), 117.07 (d, J = 12.0 Hz), 112.84 (d, J = 28.0 Hz), 48.93, 28.42. **HRMS** (ESI) calcd. for C₁₆H₁₂FN₂O ([M+H]⁺): 267.0934, Found: 267.0940.

8-fluoro-12,13-dihydro-6H-isoquinolino[2,1-a]quinazolin-6-one (2g)



80% yield (107 mg). ¹H NMR (400 MHz, CDCl₃): $\delta = 8.59$ (d, J = 8.0 Hz, 1H), 8.11 (d, *J* = 8.4 Hz, 1H), 7.61-7.43 (m, 4H), 7.33 (d, *J* = 7.6 Hz, 1H), 4.38 (t, J = 6.8 Hz, 2H), 3.30 (t, J = 6.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): $\delta = 168.56$, 161.45(d, J = 249.1 Hz), 155.04, 137.27, 135.54,

132.86, 129.76, 128.95, 127.98, 126.95, 122.30 (d, *J* = 7.0 Hz), 121.83 (d, *J* = 24.4 Hz), 116.14 (d,

J = 7.7 Hz), 114.19 (d, *J* = 22.6 Hz), 43.63, 27.12 **HRMS** (ESI) calcd. for C₁₆H₁₂FN₂O ([M+H]⁺): 267.0934, Found: 267.0940.

8-chloro-12,13-dihydro-6H-isoquinolino[2,1-a]quinazolin-6-one (2h)^[3]



6.8 Hz, 2H), 3.32 (t, *J* = 6.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): δ = 168.17, 155.24, 139.27, 135.69, 133.91, 133.83, 132.98, 131.90, 129.81, 128.42, 128.00, 127.03, 121.63, 115.66, 43.56, 27.11.

7-bromo-12,13-dihydro-6H-isoquinolino[2,1-*a*]quinazolin-6-one (2i)

Br O 79% yield (129 mg). ¹H NMR (400 MHz, CDCl₃): $\delta = 8.46$ (dd, J = 8.0, 1.6Hz, 1H), 7.73-7.71 (m, 1H), 7.52-7.47 (m, 2H), 7.44 (t, J = 7.6 Hz, 1H), 7.34 (d, J = 7.6, 2H), 4.31 (t, J = 6.8 Hz, 2H), 3.31 (t, J = 6.4 Hz, 2H).¹³C NMR (100 MHz, CDCl₃): $\delta = 168.73, 155.47, 141.71, 135.75, 133.05, 130.59, 129.81, 129.24, 128.86, 128.73, 127.98, 127.08, 119.13, 117.17, 43.57, 27.10. HRMS (ESI) calcd. for C₁₆H₁₂BrN₂O ([M+H]⁺): 327.0133, Found: 327.0139.$

9-bromo-12,13-dihydro-6H-isoquinolino[2,1-*a*]quinazolin-6-one (2j)^[1]



Hz, 2H). ¹³**C NMR** (100 MHz, CDCl₃): *δ* = 168.72, 155.45, 141.69, 135.74, 133.04, 130.58, 129.79, 129.23, 128.84, 128.72, 127.97, 127.06, 119.12, 117.15, 43.56, 27.09.

3-bromo-12,13-dihydro-6H-isoquinolino[2,1-*a*]quinazolin-6-one (2k)



84% yield (137 mg). ¹H NMR (400 MHz, CDCl₃): δ = 8.71 (d, J = 2.0 Hz, 1H), 8.39 (dd, J_I = 8.0 Hz, J_2 = 2.0 Hz, 1H), 7.82-7.75 (m, 1H), 7.66-7.45 (m, 3H), 7.20 (d, J = 8.0 Hz, 1H), 4.38 (t, J = 6.8 Hz, 2H), 3.27 (t, J = 6.8 Hz, 2H). ¹³C NMR (100 MHz, CDCl₃): 170.02, 154.60,

141.41, 136.46, 135.38, 134.81, 133.05, 131.65, 129.84, 129.50, 127.02, 122.64, 121.28, 114.80, 43.97, 27.54. **HRMS** (ESI) calcd. for C₁₆H₁₂BrN₂O ([M+H]⁺): 327.0133, Found: 327.0130.

2-phenylquinazolin-4(3H)-one (4a) ^[4]



65% yield (72 mg). ¹**H NMR** (400 MHz, DMSO-*d*₆): δ = 12.55 (s, 1H), 8.24 – 8.14 (m, 3H), 7.86-7.84 (m, 1H), 7.76 (dd, *J*₁ = 8.0 Hz, *J*₂ = 0.8 Hz, 1H), 7.63 – 7.50 (m, 4H).¹³**C NMR** (100 MHz, DMSO-*d*₆): δ = 162.97, 153.04, 149.45,

135.35, 133.43, 132.14, 129.34, 128.49, 128.23, 127.33, 126.58, 121.69.

2-(p-tolyl)quinazolin-4(3H)-one (4b) [4]



67% yield (79 mg). ¹H NMR (400 MHz, DMSO- d_6): δ = 12.40 (s, 1H), 8.03 (dd, J_1 = 20.4 Hz, J_2 = 7.6 Hz, 3H), 7.78-7.70 (m, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.47-7.38 (m, 1H), 7.27 (d, J = 8.0 Hz, 2H), 2.30 (s, 3H); ¹³C NMR

(100 MHz, DMSO-*d*₆): *δ* = 162.11, 152.06, 148.66, 141.31, 134.45, 129.71, 129.05, 127.52, 127.26, 126.27, 125.68, 120.72, 20.85.

2-(3-methoxyphenyl)quinazolin-4(3H)-one (4c) ^[5]



71% yield (90 mg). ¹H NMR (400 MHz, DMSO- d_6): $\delta = 12.56$ (s, 1H), e 8.17 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.6$ Hz, 1H), 7.90-7.71 (m, 4H), 7.59-7.42 (m, 2H), 7.16 (dd, $J_1 = 8.0$ Hz, $J_2 = 2.4$ Hz, 1H), 3.88 (s, 3H); ¹³C NMR (100

MHz, DMSO- d_6): $\delta = 163.10, 160.18, 152.89, 135.49, 134.86, 130.61, 128.39, 127.50, 126.71, 121.85, 120.97, 118.46, 113.35, 56.24.$

2-(3,5-dimethoxyphenyl)quinazolin-4(3H)-one (4d) [6]



67% yield (95 mg). ¹H NMR (400 MHz, DMSO- d_6): $\delta = 12.54$ (s, 1H), ^{DMe} 8.16 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.2$ Hz, 1H), 7.88-7.80 (m, 1H), 7.76 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$ Hz, 1H), 7.57-7.50 (m, 1H), 7.39 (d, J = 2.4 Hz, 2H), 6.70

(t, J = 2.0 Hz, 1H), 3.85 (s, 6H); ¹³**C NMR** (100 MHz, DMSO- d_6): $\delta = 162.88$, 161.13, 161.13, 152.47, 135.25, 135.17, 128.21, 127.31, 126.50, 121.69, 106.11, 104.40, 56.17.

2-(3,5-dimethylphenyl)quinazolin-4(3H)-one (4e)^[7]



65% yield (81 mg). ¹**H NMR** (400 MHz, DMSO- d_6): $\delta = 12.46$ (s, 1H), 8.19 (dd, $J_1 = 8.0$ Hz, $J_2 = 1.6$ Hz, 1H), 7.90-7.82 (m, 3H), 7.78 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$ Hz, 1H), 7.58-7.52 (m, 1H), 7.26 (s, 1H), 2.40 (s, 6H);

¹³**C** NMR (100 MHz, DMSO- d_6): $\delta = 162.64$, 152.92, 149.25, 138.23, 135.06, 133.21, 133.02, 127.92, 126.96, 126.31, 125.95, 121.43, 21.36.

2-(4-(trifluoromethoxy)phenyl)quinazolin-4(3H)-one (4f)^[7]



78% yield (119 mg). ¹**H NMR** (400 MHz, DMSO- d_6): δ = 12.66 (s, 1H), 8.31 (d, J = 8.8 Hz, 2H), 8.17 (dd, J_1 = 8.0 Hz, J_2 =1.6 Hz, 1H), 7.90-7.84 (m, 1H), 7.76 (dd, J_1 = 8.4 Hz, J_2 =1.2 Hz, 1H), 7.61-7.52 (m, 3H);

¹³**C NMR** (100 MHz, DMSO-*d*₆): δ = 172.97, 151.68, 138.60, 135.12, 130.54, 130.07, 127.91, 127.26, 126.31, 121.42, 121.32, 113.20, 92.53.

2-(4-fluorophenyl)quinazolin-4(3H)-one (4g)^[4]



65% yield (78 mg). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 12.59 (s, 1H),
8.31-8.22 (m, 2H), 8.16 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.6 Hz, 1H), 7.89-7.81 (m,
1H), 7.74 (dd, *J*₁ = 8.0 Hz, *J*₂ = 1.2 Hz, 1H), 7.56-7.49 (m, 1H), 7.40 (t, *J*

= 8.8 Hz, 2H); ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 165.75 (d, *J* = 247.8 Hz), 162.67, 151.83, 149.12, 135.12, 130.89 (d, *J*=9.0 Hz), 129.71, 127.94, 127.09, 126.32, 121.36, 116.11 (d, *J* = 21.90 Hz).

2-(2,5-difluorophenyl)quinazolin-4(3H)-one (4h)^[8]



127.88, 127.60, 126.19, 123.81 (dd, J_1 = 15.8 Hz, J_2 = 8.5 Hz), 121.52, 119.64 (dd, J_1 = 23.7 Hz, J_2 = 8.8 Hz), 118.33 (dd, J_1 = 24.4 Hz, J_2 = 8.9 Hz), 117.67 (dd, J_1 = 25.8 Hz, J_2 = 2.8 Hz).

3-methyl-2-phenylquinazolin-4(3H)-one (4i)^[4]



66% yield (78 mg). ¹**H NMR** (400 MHz, CDCl₃): *δ* = 8.39 (d, *J* = 8.0 Hz, 1H), 7.80 (s, 2H), 7.67-7.54 (m, 6H), 3.56 (s, 1H); ¹³**C NMR** (100 MHz, CDCl₃): *δ* = 162.66, 156.08, 147.27, 135.35, 134.26, 130.03, 128.84, 127.96, 127.44, 126.95,

126.63, 120.48, 34.23.

2-(3,5-dimethoxyphenyl)-3-methylquinazolin-4(3H)-one (4j)^[9]



 d_6): $\delta = 162.06, 160.92, 156.36, 147.49, 137.66, 134.87, 127.70, 127.44, 126.59, 120.76, 106.70, 102.03, 56.03, 34.19.$

2-(3,5-dimethylphenyl)-3-methylquinazolin-4(3H)-one (4k)^[9]



77% yield (102 mg). ¹H NMR (400 MHz, DMSO- d_6): $\delta = 8.18$ (dd, $J_1 = 8.0$ Hz, $J_2 = 1.2$ Hz, 1H), 7.85-7.81 (m, 1H), 7.66 (dd, $J_1 = 8.4$ Hz, $J_2 = 1.2$ Hz, 1H), 7.56-7.50 (m, 1H), 7.26 (s, 2H), 7.18 (s, 1H), 3.37 (s, 5H), 2.39-2.35 (m, 6H); ¹³C NMR (100 MHz, DMSO- d_6): $\delta = 162.00, 156.65, 147.44,$

138.02, 135.63, 134.66, 131.43, 127.48, 127.13, 126.43, 126.15, 120.44, 34.26, 21.20.

5-fluoro-2-phenylquinazolin-4(3H)-one (4l)^[10]



75% yield (90 mg). ¹H NMR (400 MHz, DMSO- d_6): $\delta = 12.57$ (s, 1H), 8.17– 8.15 (m, 2H), 7.81-7.76 (m, 1H), 7.59 – 7.52 (m, 4H), 7.27-7.21 (m, 1H). ¹³C NMR (100 MHz, DMSO- d_6): $\delta = 162.35$ (d, J = 261.0 Hz), 160.12, 153.79,

151.39, 135.61 (d, *J* = 10.7 Hz), 132.73, 132.19, 129.14, 128.38, 124.08, 113.30 (d, *J* = 20.2 Hz), 110.96 (d, *J* = 6.1 Hz).

2-(3,5-dimethoxyphenyl)-6-fluoroquinazolin-4(3H)-one (4m)^[4]



70% yield (105 mg). ¹H NMR (400 MHz, DMSO- d_6):12.62 (s, 1H), 7.85–7.81 (m, 2H), 7.75-7.70 (m, 1H), 7.37 (d, J = 2.4 Hz, 2H), 6.70 (t, J = 2.0 Hz, 1H), 3.84 (s, 6H). ¹³C NMR (100 MHz, DMSO- d_6): $\delta = 161.75$ (d, J = 243.9 Hz), 161.01, 151.92, 145.92, 134.88, 132.19 (d, J

= 17.5 Hz), 129.15, 123.69 (d, *J* = 24.1 Hz), 122.8 (d, *J* = 8.0 Hz), 111.13 (d, *J* = 23.2 Hz), 105.99, 104.27, 56.29.

2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one (6a)^[1]

74% yield (69 mg). ¹H NMR (400 MHz, CDCl₃):
$$\delta = 8.30$$
 (dt, $J_1 = 8.0$ Hz, $J_2 = 1.6$
Hz, 1H), 7.75-7.66 (m, 1H), 7.48-7.40 (m, 1H), 7.22 (d, $J = 8.0$ Hz, 1H), 4.27 (t, $J = 7.6$ Hz, 2H), 3.20 (t, $J = 8.4$ Hz, 2H), 2.44 (q, $J = 8.0$ Hz, 2H). ¹³C NMR (100

MHz, CDCl₃): *δ* = 170.17, 166.46, 138.66, 133.67, 128.83, 125.88, 118.77, 114.51, 48.75, 32.83, 18.70.

5,6-dihydrobenzo[4,5]imidazo[2,1-a]isoquinoline (6b)^[4]



79% yield (87 mg). ¹H NMR (400 MHz, CDCl₃): δ = 8.35-8.34 (m, 1H), 7.937.80 (m, 1H), 7.47-7.26 (m, 6H), 4.34 (t, J = 8.0 Hz, 2H), 3.35-3.23 (m, 2H).

¹³C NMR (100 MHz, CDCl₃): δ = 149.13, 143.91, 134.67, 134.31, 130.19, 128.12, 127.77, 126.66, 125.67, 122.71, 122.50, 119.76, 109.09, 40.42, 28.26.

1,2-diphenyl-1H-benzo[d]imidazole (6c)^[4]



66% yield (89 mg). ¹H NMR (400 MHz, DMSO-*d*₆): δ = 7.81-7.79 (m, 1H), 7.58–7.52 (m, 5H), 7.44-7.26 (m, 7H), 7.20–7.18 (m, 1H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ = 152.50, 143.22, 137.75, 137.13, 130.70, 130.50, 130.19,

 $129.79,\,129.51,\,129.02,\,128.19,\,124.01,\,123.40,\,120.06,\,111.13.$

1-benzyl-2-phenyl-1H-benzo[d]imidazole (6d)^[11]



28% yield (39.8 mg). ¹H NMR (400 MHz, CDCl₃): δ = 7.90 (d, J = 8.0 Hz, 1H), 7.73-7.71 (m, 2H), 7.51-7.46 (m, 3H), 7.38-7.22 (m, 6H), 7.15-7.12 (m, 2H), 5.48 (s, 2H). ¹³C NMR (100 MHz, CDCl₃): 154.19, 143.16, 136.40, 136.06, 130.05, 129.96, 129.28, 129.09, 128.79, 127.80, 125.98,

123.08, 122.72, 120.00, 110.57, 48.40.

12,12',13,13'-tetrahydro-6H,6'H-4b,4'b-bibenzo[4,5][1,3]oxazino[2,3-a]isoquinoline (6e)^[4]



65% yield (154 mg). ¹**H NMR** (400 MHz, CDCl₃): δ = 8.16 (dd, J_1 = 7.6 Hz, J_2 =1.6 Hz, 2H), 7.61 (dd, J_1 = 7.2 Hz, J_2 = 2.4 Hz, 2H), 7.56-7.51 (m, 2H), 7.44-7.39 (m, 6H), 7.33-7.20 (m, 4H), 4.66 (d, J = 11.6

Hz, 2H), 4.52-4.43 (m, 2H), 4.12-4.01 (m, 2H), 3.91-3.63 (m, 2H), 3.31-3.21 (m, 2H), 3.16-3.05 (m, 2H). ¹³**C NMR** (100 MHz, CDCl₃): *δ* = 165.74, 141.31, 138.50, 137.76, 132.51, 130.79, 129.41, 129.07, 128.84, 128.34, 127.35, 127.15, 125.97, 61.96, 50.19, 28.59.

Reference:

- [1]. Sun, Y. Hu, S. Z. Nie, Y. Y. Yan, X. J. Zhang, M. Yan, Adv. Synth. Catal., 2013, 355, 2179–2184.
- [2]. Hikawa, Y. Ino, H. Suzuki, Y. Yokoyama, J. Org. Chem. 2012, 77, 7046-7051.
- [3]. Q. Y. Li, S. Y. Cheng, H. T. Tang, Y. M. Pan, Green Chem., 2019, 21, 5517–5520.
- [4]. S. M. Patel, H. Chada, S. Biswal, S. Sharma, D. S. Sharada, Synthesis 2019, 51, 3160–3170.
- [5]. J. K. Laha, K. S. S. Tummalapalli, A. Nair, N. Patel, J. Org. Chem. 2015, 80, 11351–11359.
- [6]. R. Sharma, R. A. Vishwakarma, S. B. Bharate, Adv. Synth. Catal. 2016, 358, 3027–3033.
- [7]. K. Upadhyaya, R. K. Thakur, S. K. Shukla, R. P. Tripathi, J. Org. Chem. 2016, 81, 5046-5055.
- [8]. S. Hao, J. Yang, P. Liu, J. Xu, C. Yang, F. Li, Org. Lett. 2021, 23, 2553-2558.
- [9]. Y. Jang, S. B. Lee, J. Hong, S. Chun, J. Lee, S. Hong, Org. Biomol. Chem. 2020, 18, 5435-5441.
- [10]. H. Hikawa, Y. Ino, H. Suzuki, Y. Yokoyama, J. Org. Chem. 2012, 77, 7046-7051.
- [11]. P. H. Wang, J. Y. Wang, C. T. Au, R.H. Qiu, X. H. Xu, S. F. Yin, Adv. Synth. Catal. 2016, 358, 1302–1308

7. NMR spectra







2b



2c





2e



2f





2h





2j







4a



4b











4g



4h



4i

90 80 70 f1 (ppm)



75 170 165 160 155 150 145 140 135 130 125 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50 45 40 35 30 f1 (ppm)









6a







6b







6d









8. HRMS spectra

2b

OMe O



Conf(%) Formula n/a C16 H12 N2 0 F

5.0

mDa 0.4

Calc. Mass 267.0934

Mass 267.0938

10.0

PPM 1.5

50.0

DBE 11.5

i-FIT Norm 1263.1 n/a

2f

Elemental Composition Report

Page 1

Single Mass Analysis Tolerance = 10.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions 309 formula(e) evaluated with 1 results within limits (up to 50 closest results for each mass) Elements Used: C: 16-16 H: 0-100 N: 0-10 O: 0-10 F: 1-3 0114-1-2r-2f 115 (0.652)



Mass Calc. Mass mDa PPM DBE i⊣FIT Norm Conf(%) Formula 267.0940 267.0934 0.6 2.2 11.5 1147.7 n/a n/a C16 H12 N2 0 F

2g



Elemental Composition Report

Page 1

Single Mass Analysis Tolerance = 30.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions 172 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 16-17 H: 10-20 N: 0-6 O: 0-8 CI: 0-2 F: 1-1







Elemental Composition Report

Page 1

Single Mass Analysis

Tolerance = 30.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3

Monoisotopic Mass, Even Electron Ions 440 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 16-17 H: 10-20 N: 0-6 O: 0-8 Cl: 0-2 Br: 0-2



Mass Calc. Mass mDa PPM DBE i-FLT Norm Conf (%) Formula 327.0139 327.0133 0.6 1.8 11.5 733.8 n/a n/a C16 H12 N2 0 Br

2k



Elemental Composition Report

Page 1

Single Mass Analysis Tolerance = 30.0 PPM / DBE: min = -1.5, max = 50.0 Element prediction: Off Number of isotope peaks used for i-FIT = 3 Monoisotopic Mass, Even Electron Ions 440 formula(e) evaluated with 1 results within limits (up to 50 best isotopic matches for each mass) Elements Used: C: 16-17 H: 10-20 N: 0-6 O: 0-8 CI: 0-2 Br: 0-2

